QualityDipStocks / Health Care · Pharmaceuticals
Nuvation Bio NUVB
Outside our quality screen, so we don’t track its dips. It’s 52% below its 52-week high.
Outside our quality screen, 20% under its Market Value. No fair value estimate for now: its free cash flow is negative.
Worth knowing
- Net cash = 26% of its market cap
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $5.76price −20%
- Off 52-wk high
- −52%
- Risk vs market
- Highbeta 1.61
52-week range 10% of the way from its 52-week low to its high
Price $4.59Market Value $5.76
2 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for NUVB: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much NUVB moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings much more than the market, and its own price swings are 6.4× the S&P 500’s.
- Beta vs S&P 500
- 1.61
- Volatility
- 82% vs 13% SPY
- Correlation SPY
- 0.25
- Correlation QQQ
- 0.22
Valuation details
MV $5.76
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 2 of 5
Balance sheetNet cash of $412M: cash and short-term investments exceed debt (Jun 30, 2026).
ValuationTrades 20.3% below its Market Value of $5.76, the average price paid since the Aug 6 filing.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$181M over the last 12 months), so there’s no cash-flow value under the price.
Balance sheetOperating income covers interest only -5.2× over the last 12 months.
ProfitabilityLost $150M over the last 12 months (net income, SEC filings).
ProfitabilityReturn on equity fell 54 points in two fiscal years, to -67% in FY2025.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%.
All fundamentals
ROE -48%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- n/anegative EBITDA
- Price / sales
- 9.42×
- Price / book
- 6.30×
- Market cap
- $1.6Blisted
- Enterprise value
- $1.2B
Growth
- Revenue, 12 months
- $170M
- Sales growth, 12 months
- n/an/m: revenue a year ago near zero
- Sales growth, 3 yrs
- n/anot reported in its SEC filings
- Diluted EPS, 12 months
- −$0.44
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$150M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- −81.0%
- Net margin
- −88.2%
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- −48%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $661M
- Total debt
- $249M
- Net cash
- $412M
- Debt / equity
- 0.98×
- Interest coverage
- -5.2×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +2.4%diluted shares vs a year ago
- Stock-based comp
- $36M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Nuvation Bio’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
Sales +556%
- Gross margin88%
- Operating margin−161%
- Return on equity−48%
- Sales growth (latest quarter vs year-ago quarter)+556%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $4.59
- 52-wk lowlowest close, 1 year$4.05−11.8%
- PriceMon Nov 2 close$4.59you are here
- Market Valueavg paid since Aug 6$5.76+25.5%
- 52-wk highhighest close, 1 year$9.54+107.8%
Momentum & 52-week range
RSI 38 · 5 days +1.8%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 4
- DateWed Nov 4, after the close
- Consensus EPS($0.11)
- Year-ago EPS($0.16)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
NUVB is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Nuvation Bio in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.